Amlodipine Besylate side effects: what 145,623 FDA adverse event reports show
Drug class
Calcium channel blocker and may be
Brand names
Katerzia
Who reports
145,623 reports · 69% serious · 13,152 with death outcome · 57% female
Used for
KATERZIA is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) KATERZIA is indicated for the treatment of hypertension in adults and children 6 years and older, to lower blood pressure.
What it is
Amlodipine is a fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,136 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Congenital hiatus hernia | 107 | 134.7 103.4–175.6ROR 134.8 · calibrated p 2e-8 ✓ | 68.6 EB05 58.3 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=107 · ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Neurologic neglect syndrome | 218 | 91.8 77.4–108.8ROR 91.9 · calibrated p 3e-7 ✓ | 55.7 EB05 49.8 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=218 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Carotid artery thrombosis | 220 | 49.8 42.7–58.1ROR 49.9 · calibrated p 2e-5 ✓ | 37.0 EB05 33.0 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=220 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Adjustment disorder | 216 | 28.4 24.6–32.9ROR 28.5 · calibrated p 4e-4 ✓ | 23.8 EB05 21.2 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=215 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Chronic kidney disease-mineral and bone disorder | 168 | 26.5 22.5–31.2ROR 26.5 · calibrated p 5e-4 ✓ | 22.4 EB05 19.7 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=168 | not reported in cached trials |
| Nephrogenic anaemia | 723 | 26.2 24.2–28.4ROR 26.3 · calibrated p 5e-4 ✓ | 22.2 EB05 20.9 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=722 | not reported in cached trials |
| Multiple drug therapy | 107 | 25.9 21.1–31.9ROR 25.9 · calibrated p 6e-4 ✓ | 22.0 EB05 18.7 · IC025 +4.0 3/3 methods agree | Reporting / coding artifact | serious n=106 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Hyperparathyroidism secondary | 366 | 24.2 21.7–27.0ROR 24.3 · calibrated p 8e-4 ✓ | 20.8 EB05 19.1 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=365 | NCT00170950: 1/5,757 (0.0%) on Amlodipine Besylate (serious AE) |
| Blood pressure inadequately controlled | 662 | 17.5 16.2–19.0ROR 17.6 · calibrated p 0.004 ✓ | 15.7 EB05 14.7 · IC025 +3.8 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=437 | NCT00170950: 1/5,757 (0.0%) on Amlodipine Besylate (serious AE) |
| Sedation complication | 260 | 16.6 14.6–18.9ROR 16.6 · calibrated p 0.005 ✓ | 14.9 EB05 13.5 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | serious n=260 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Nasal oedema | 169 | 14.9 12.7–17.4ROR 14.9 · calibrated p 0.007 ✓ | 13.5 EB05 11.9 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=164 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Personality disorder | 239 | 14.3 12.5–16.3ROR 14.3 · calibrated p 0.009 ✓ | 13.0 EB05 11.7 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=238 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Gingival hypertrophy | 134 | 14.0 11.7–16.7ROR 14.0 · calibrated p 0.010 ✓ | 12.8 EB05 11.0 · IC025 +3.3 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Creatinine renal clearance decreased | 322 | 12.4 11.1–13.9ROR 12.4 · calibrated p 0.015 ✓ | 11.5 EB05 10.4 · IC025 +3.3 3/3 methods agree | Lab value / disease marker | serious n=315 · ♀ 100% (drug 57%) | not reported in cached trials |
| Rebound acid hypersecretion | 230 | 11.6 10.1–13.3ROR 11.6 · calibrated p 0.019 ✓ | 10.7 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=230 | not reported in cached trials |
| Nephrogenic systemic fibrosis | 223 | 11.2 9.8–12.9ROR 11.3 · calibrated p 0.022 ✓ | 10.4 EB05 9.3 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=222 | not reported in cached trials |
| Schizoaffective disorder | 127 | 10.9 9.1–13.1ROR 10.9 · calibrated p 0.025 ✓ | 10.0 EB05 8.6 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=127 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| End stage renal disease | 1,203 | 10.0 9.4–10.6ROR 10.1 · calibrated p 0.032 ✓ | 9.4 EB05 8.9 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 7.8 | not reported in cached trials |
| Distributive shock | 143 | 9.9 8.4–11.7ROR 9.9 · calibrated p 0.035 ✓ | 9.2 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=143 · 100% clinician | not reported in cached trials |
| Essential hypertension | 166 | 9.8 8.4–11.5ROR 9.8 · calibrated p 0.036 ✓ | 9.1 EB05 8.0 · IC025 +2.9 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=148 | NCT00170950: 1/5,740 (0.0%) on Amlodipine Besylate (serious AE) |
| Blood pressure systolic abnormal | 151 | 9.2 7.8–10.9ROR 9.2 · calibrated p 0.043 ✓ | 8.6 EB05 7.5 · IC025 +2.8 3/3 methods agree | Likely indication confounding term in indications | serious n=149 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Burns second degree | 100 | 8.7 7.1–10.6ROR 8.7 · calibrated p 0.054 | 8.0 EB05 6.8 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=96 · ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Skin induration | 116 | 8.5 7.1–10.3ROR 8.5 · calibrated p 0.057 | 7.9 EB05 6.7 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=113 · 100% clinician | not reported in cached trials |
| Breath sounds abnormal | 271 | 8.3 7.4–9.4ROR 8.3 · calibrated p 0.060 | 7.8 EB05 7.1 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=262 | not reported in cached trials |
| Carotid artery stenosis | 186 | 8.0 6.9–9.3ROR 8.0 · calibrated p 0.068 | 7.5 EB05 6.6 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=186 · 100% clinician | NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE) |
| Hyperphosphataemia | 112 | 8.0 6.6–9.6ROR 8.0 · calibrated p 0.069 | 7.4 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=112 · ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Renal failure chronic | 401 | 7.8 7.0–8.6ROR 7.8 · calibrated p 0.073 | 7.3 EB05 6.8 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious PRR 6.1 | NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE) |
| Benign prostatic hyperplasia | 259 | 7.5 6.6–8.5ROR 7.5 · calibrated p 0.081 | 7.1 EB05 6.4 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=253 · ♀ 0% (drug 57%) | NCT00170950: 13/5,740 (0.2%) on Amlodipine Besylate (serious AE) |
| Hyperlipidaemia | 591 | 7.4 6.8–8.1ROR 7.4 · calibrated p 0.083 | 7.1 EB05 6.6 · IC025 +2.7 3/3 methods agree | Likely indication confounding term in indications | serious PRR 6.2 | not reported in cached trials |
| Blood pressure diastolic abnormal | 118 | 6.9 5.7–8.3ROR 6.9 · calibrated p 0.106 | 6.5 EB05 5.5 · IC025 +2.4 3/3 methods agree | Likely indication confounding term in indications | serious n=116 · ♀ 100% (drug 57%) · 100% clinician | not reported in cached trials |
| Lacunar infarction | 106 | 6.6 5.5–8.1ROR 6.6 · calibrated p 0.118 | 6.2 EB05 5.3 · IC025 +2.3 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=105 · ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Ischaemic cardiomyopathy | 137 | 6.6 5.6–7.9ROR 6.6 · calibrated p 0.118 | 6.2 EB05 5.4 · IC025 +2.4 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=136 · ♀ 0% (drug 57%) · 100% clinician | NCT00170950: 1/5,740 (0.0%) on Amlodipine Besylate (serious AE) |
| Ventricular hypertrophy | 111 | 6.6 5.4–7.9ROR 6.6 · calibrated p 0.121 | 6.2 EB05 5.3 · IC025 +2.3 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=111 · ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Hemiplegia | 356 | 6.4 5.7–7.1ROR 6.4 · calibrated p 0.128 | 6.1 EB05 5.6 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious PRR 5.2 · ♀ 80% (drug 57%) | NCT00170950: 1/5,740 (0.0%) on Amlodipine Besylate (serious AE) |
| Arterial occlusive disease | 334 | 6.3 5.7–7.0ROR 6.3 · calibrated p 0.132 | 6.0 EB05 5.5 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious PRR 5.2 | NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE) |
| Blood calcium decreased | 470 | 6.2 5.7–6.8ROR 6.2 · calibrated p 0.137 | 6.0 EB05 5.5 · IC025 +2.4 3/3 methods agree | Likely indication confounding term in indications | serious PRR 5.9 · ♀ 81% (drug 57%) | not reported in cached trials |
| Blood phosphorus increased | 113 | 6.2 5.1–7.5ROR 6.2 · calibrated p 0.142 | 5.8 EB05 5.0 · IC025 +2.2 3/3 methods agree | Lab value / disease marker | serious n=106 · ♀ 0% (drug 57%) · 100% clinician | not reported in cached trials |
| Gangrene | 247 | 6.1 5.3–6.9ROR 6.1 · calibrated p 0.147 | 5.8 EB05 5.2 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious n=246 · ♀ 100% (drug 57%) | NCT00170950: 1/5,757 (0.0%) on Amlodipine Besylate (serious AE) |
| Aortic stenosis | 141 | 6.0 5.1–7.1ROR 6.0 · calibrated p 0.150 | 5.7 EB05 5.0 · IC025 +2.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=141 · ♀ 0% (drug 57%) · 100% clinician | NCT00170950: 3/5,740 (0.1%) on Amlodipine Besylate (serious AE) |
| Diastolic dysfunction | 125 | 6.0 5.0–7.2ROR 6.0 · calibrated p 0.153 | 5.7 EB05 4.9 · IC025 +2.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=124 | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Kidney injury | 9,547 | 3.13.0–3.1 | signal |
| Hyponatraemia | 1,597 | 2.92.8–3.0 | signal |
| Heart failure | 3,336 | 2.72.6–2.8 | signal |
| Stroke | 4,342 | 2.52.5–2.6 | signal |
| Anaemia | 4,980 | 2.42.3–2.5 | signal |
| Myocardial infarction | 3,305 | 2.32.3–2.4 | signal |
| Gi bleeding | 2,902 | 2.32.2–2.4 | signal |
| Rhabdomyolysis / myopathy | 1,262 | 2.32.1–2.4 | signal |
| Arrhythmia / qt | 2,994 | 2.22.2–2.3 | signal |
| Fall / fracture | 5,783 | 2.22.2–2.3 | signal |
| Hypoglycaemia | 1,322 | 2.01.9–2.1 | raised |
| Interstitial lung disease | 1,296 | 2.01.9–2.1 | raised |
| Serious infection | 10,316 | 1.91.9–2.0 | raised |
| Hyperglycaemia / diabetes | 4,343 | 1.81.8–1.9 | raised |
| Thrombocytopenia | 2,435 | 1.61.5–1.7 | raised |
| Depression | 3,033 | 1.61.5–1.6 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Amlodipine Besylate as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (11 of 40 signal terms matched).
- NCT01252563 — Amlodipine 10mg Drug Use Investigation (N=14141, phase n/a; 70 AE terms posted; arms: Amlodipine 10 mg Tablet)
- NCT00170950 — Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (N=11506, PHASE3; 1077 AE terms posted; arms: Benazepril / Amlodipine; Benazepril / HCTZ)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 9,731 | 1.8 1.8–1.8ROR 1.9 · calibrated p 0.872 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.8 | NCT00170950: 3/5,740 (0.1%) on Amlodipine Besylate (serious AE) |
| Nausea | 8,345 | 1.5 1.5–1.6ROR 1.6 · calibrated p 0.681 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.6 | NCT00170950: 9/5,740 (0.2%) on Amlodipine Besylate (serious AE) |
| Diarrhoea (diarrhea) | 7,913 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.845 | 1.8 EB05 1.7 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.7 | NCT00170950: 17/5,740 (0.3%) on Amlodipine Besylate (serious AE) |
| Dyspnoea (shortness of breath) | 7,834 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.979 | 2.0 EB05 2.0 · IC025 +1.0 | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 1.9 | NCT00170950: 40/5,740 (0.7%) on Amlodipine Besylate (serious AE) |
| Drug ineffective (drug did not work) | 7,077 | 0.8 0.8–0.8ROR 0.8 · calibrated p 0.162 | 0.8 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.0 | not reported in cached trials |
| Pain | 6,809 | 1.6 1.6–1.6ROR 1.6 · calibrated p 0.725 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.9 · serious PRR 1.6 | NCT00170950: 21/5,740 (0.4%) on Amlodipine Besylate (serious AE) |
| Dizziness | 6,554 | 1.9 1.9–2.0ROR 1.9 · calibrated p 0.916 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | NCT01252563: 45/13,343 (0.3%) on Amlodipine Besylate |
| Headache | 6,452 | 1.5 1.5–1.5ROR 1.5 · calibrated p 0.649 | 1.5 EB05 1.5 · IC025 +0.5 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.6 | NCT01252563: 14/13,343 (0.1%) on Amlodipine Besylate |
| Asthenia (weakness) | 5,760 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.915 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 2.0 | NCT00170950: 9/5,740 (0.2%) on Amlodipine Besylate (serious AE) |
| Fall | 5,398 | 2.4 2.3–2.4ROR 2.4 · calibrated p 0.852 | 2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 2.1 | NCT00170950: 13/5,740 (0.2%) on Amlodipine Besylate (serious AE) |
| Pneumonia (lung infection) | 5,383 | 2.4 2.4–2.5ROR 2.5 · calibrated p 0.824 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.0 · serious PRR 2.1 | NCT01252563: 7/13,343 (0.1%) on Amlodipine Besylate (serious AE) |
| Vomiting | 5,304 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.744 | 1.6 EB05 1.6 · IC025 +0.7 | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 1.7 | NCT00170950: 13/5,740 (0.2%) on Amlodipine Besylate (serious AE) |
| Off label use (used outside approved label) | 5,302 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.227 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.0 | not reported in cached trials |
| Hypertension (high blood pressure) | 5,167 | 3.6 3.5–3.7ROR 3.7 · calibrated p 0.446 | 3.5 EB05 3.4 · IC025 +1.8 3/3 methods agree | Likely indication confounding term in indications | age-adj. PRR 3.1 · serious PRR 3.1 | NCT00170950: 3/5,740 (0.1%) on Amlodipine Besylate (serious AE) |
| Death | 4,847 | 0.8 0.8–0.8ROR 0.8 · calibrated p 0.185 | 0.8 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Outcome field, not a reaction | age-adj. PRR 0.7 · serious PRR 0.7 | NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Congenital hiatus hernia — n=107, PRR 134.7
- Neurologic neglect syndrome — n=218, PRR 91.8
- Carotid artery thrombosis — n=220, PRR 49.8
- Adjustment disorder — n=216, PRR 28.4
- Chronic kidney disease-mineral and bone disorder — n=168, PRR 26.5
- Nephrogenic anaemia — n=723, PRR 26.2
- Hyperparathyroidism secondary — n=366, PRR 24.2 (also seen in trial arm)
- Nasal oedema — n=169, PRR 14.9
- Personality disorder — n=239, PRR 14.3
- Rebound acid hypersecretion — n=230, PRR 11.6
✓ A hand-written Bradford Hill causality assessment exists for this drug: Amlodipine (dihydropyridine CCBs) ↔ Peripheral oedema.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Amlodipine Besylate?
In FDA FAERS, the most frequently co-reported reaction terms for Amlodipine Besylate are fatigue, nausea, diarrhoea, dyspnoea, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Amlodipine Besylate have an FDA boxed warning?
No. The FDA label retrieved for Amlodipine Besylate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Amlodipine Besylate causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID df673a4d-acb8-444c-a472-c87ab8cbd366, effective 20251216; matched on
openfda.generic_name.exact:"AMLODIPINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 2162 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,176 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
AMLODIPINE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.